Cargando…
A conjugated mTOR/MEK bifunctional inhibitor as potential polypharmacological anticancer agent: the prototype compound discovery
mTOR/MEK bifunctional inhibitors have the potential to surmount the drug resistance aroused from cross talk between PI3K/Akt/mTOR (PAM) and Ras/MEK/ERK pathways. Herein, we report the discovery of a conjugated dual-targeted molecule, compound 13, as the prototype mTOR/MEK bifunctional inhibitor. It...
Autores principales: | Tao, Qiangqiang, Fang, Fang, Li, Jiaming, Wang, Yong, Zhao, Can, Liang, Jingtai, Ma, Xiaodong, Wang, Hao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223898/ https://www.ncbi.nlm.nih.gov/pubmed/32435126 http://dx.doi.org/10.1007/s00044-020-02502-x |
Ejemplares similares
-
Discovery of talmapimod analogues as polypharmacological anti-inflammatory agents
por: Liu, Wandong, et al.
Publicado: (2019) -
Combination MEK and mTOR inhibitor therapy is active in models of glioblastoma
por: Schreck, Karisa C, et al.
Publicado: (2020) -
Mutant HRAS as novel target for MEK and mTOR inhibitors
por: Kiessling, Michael K., et al.
Publicado: (2015) -
Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases
por: Apsel, Beth, et al.
Publicado: (2008) -
Evolution of kinase polypharmacology across HSP90 drug discovery
por: Antolin, Albert A., et al.
Publicado: (2021)